Начало › Рак на гърдата › Калифорния › San Francisco
Клинични проучвания за Рак на гърдата в San Francisco, CA
43 проучвания за Рак на гърдата търсят участници в обекти в и около San Francisco (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Набиране на участнициФаза 1/2
- Research Site, San Francisco
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Набиране на участнициФаза 3
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Набиране на участници
- Kaiser Permanente-San Francisco, San Francisco
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Набиране на участнициФаза 2
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Набиране на участнициФаза 3
- Clinical Trial Site, San Francisco
- Clinical Trial Site, San Francisco
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Набиране на участнициФаза 3
- Kaiser Permanente, San Francisco
- UCSF Medical Center at Mission Bay, San Francisco
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Набиране на участнициЗдравите доброволци са добре дошли
- University of California San Francisco, San Francisco
Pulsed Electric Field Ablation for Metastatic Breast Cancer
Набиране на участници
- University of California San Francisco, San Francisco
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Набиране на участнициФаза 3
- UCSF Zuckerberg SF General, San Francisco
- University of California, San Francisco (UCSF), San Francisco
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Набиране на участнициФаза 1
- UCSF Medical Center at Mission Bay, San Francisco
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Набиране на участнициФаза 1/2
- UCSF Helen Diller Family CCC, San Francisco
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Набиране на участнициФаза 1/2
- University of California, San Francisco, San Francisco
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- University of California-San Fransisco, San Francisco
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Набиране на участнициНаблюдателно проучване
- University of California, San Francisco, San Francisco
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Набиране на участнициФаза 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Набиране на участнициФаза 2
- University of San Francisco, San Francisco
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Набиране на участнициФаза 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- University of California San Francisco, San Francisco
Generative AI Patient Education Module for Breast Oncology
Набиране на участници
- University of California, San Francisco, San Francisco
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Набиране на участнициФаза 3
- University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco
E-Mindfulness Approaches for Living After Breast Cancer
Набиране на участнициФаза 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Набиране на участнициФаза 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Набиране на участнициФаза 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer
Набиране на участнициНаблюдателно проучване
- University of California, San Francisco, San Francisco
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
Набиране на участнициФаза 3
- University of California at San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Набиране на участнициФаза 2
- University of California San Francisco (UCSF), San Francisco
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Набиране на участнициФаза 2
- UCSF Medical Center-Mission Bay/Benioff Children's Hospital, San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Набиране на участнициФаза 2
- University of California San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Набиране на участници
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Набиране на участнициФаза 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction
Набиране на участнициНаблюдателно проучване
- University of California, San Francisco
Microbiome and Association With Implant Infections
Набиране на участнициФаза 2
- University of California, San Francisco, San Francisco
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Kaiser Permanente-San Francisco, San Francisco
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Набиране на участнициФаза 2
- University of California San Francisco (Data collection only), San Francisco
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Набиране на участнициФаза 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набиране на участнициФаза 1
- University of California San Francisco, San Francisco
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Набиране на участници
- UCSF Breast Care Center, San Francisco
Patient Care Outreach, Navigation, Technology and Support 2.0
Набиране на участници
- Zuckerberg San Francisco General Hospital, San Francisco
- University of California, San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- University of California, San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, San Francisco
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Набиране на участнициНаблюдателно проучване
- UCSF Breast Care Center, San Francisco
Проучвания за Рак на гърдата в други градове
- New York City, NY136 проучвания
- Houston, TX126 проучвания
- Boston, MA112 проучвания
- Nashville, TN81 проучвания
- Los Angeles, CA73 проучвания
- Edison, NJ68 проучвания
- St. Louis, MO64 проучвания
- Queens, NY64 проучвания
- Durham, NC64 проучвания
- Chicago, IL59 проучвания
- Philadelphia, PA56 проучвания
- Dallas, TX55 проучвания
Други проучвания в San Francisco
- Рак на простатата45 проучвания
- Рак на белия дроб с недребноклетъчен тип36 проучвания
- Рак (всички видове)35 проучвания
- Сърдечна недостатъчност29 проучвания
- Метастатичен рак28 проучвания
- Рак на белия дроб22 проучвания
- Меланом22 проучвания
- Рак на панкреаса20 проучвания
- Рак на яйчниците19 проучвания
- Колоректален рак18 проучвания
- Сърдечно-съдово заболяване18 проучвания
- Глиобластом17 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.